Document:

Exhibit 10.19

 

 

October 8, 2021

 

Board of Directors

Tenon Medical, Inc.

 

Dear Board of Directors,

 

I hereby accept my election to the Board of Directors
of Tenon Medical, Inc. (the “Company"), which is effective on the date Tenon Medical's common stock is first listed
on Nasdaq. I hereby consent to being named in the Company's registration statement and the inclusion of any of my biographical
and other information required to be included therein pursuant to federal securities laws.

 

Sincerely,

 

	/s/ Frank Fischer	 
	Frank Fischer	 

 

104 Cooper Court | Los Gatos, CA | 95032Exhibit 10.20

 

 

October 8, 2021

 

Board of Directors

Tenon Medical Inc.

 

Dear Board of Directors,

 

I hereby accept my election to the Board of Directors
of Tenon Medical, Inc. (the “Company"), which is effective on the date Tenon Medical's common stock is first listed
on Nasdaq. I hereby consent to being named in the Company's registration statement and the inclusion of any of my biographical
and other information required to be included therein pursuant to federal securities laws.

 

Sincerely,

 

	/s/ Ivan Howard	 
	Ivan Howard	 

 

104 Cooper Court | Los Gatos, CA | 95032Exhibit 10.21

 

 

October 8, 2021

 

Board of Directors

Tenon Medical, Inc.

 

Dear Board of Directors,

 

I hereby accept my election
to the Board of Directors of Tenon Medical, Inc. (the “Company"), which is effective on the date Tenon Medical's common
stock is first listed on Nasdaq. I hereby consent to being named in the Company's registration statement and the inclusion of any
of my biographical and other information required to be included therein pursuant to federal securities laws.

 

Sincerely,

 

	/s/ Stephen Hochschuler	 
	Dr. Stephen Hochschuler	 

 

104 Cooper Court | Los Gatos, CA | 95032Exhibit 10.22

 

 

October 8, 2021

 

Board of Directors

Tenon Medical, Inc.

 

Dear Board of Directors,

 

I hereby accept my election to the Board
of Directors of Tenon Medical, Inc. (the “Company"), which is effective on the date Tenon Medical's common stock is
first listed on Nasdaq. I hereby consent to being named in the Company's registration statement and the inclusion of any of my
biographical and other information required to be included therein pursuant to federal securities laws.

 

Sincerely,

 

	/s/ Robert Weigle	 
	Robert Weigle	 

 

104 Cooper Court | Los Gatos, CA | 95032Exhibit 10.23 

 

TENON MEDICAL, INC.

 

EXCHANGE AGREEMENT

 

This Exchange Agreement
(this “Agreement”) dated as of October 28, 2021 is entered into by and between Tenon Medical, Inc., a Delaware
corporation (the “Company”), Zühlke Ventures AG, a Swiss company (the “Purchaser”),
and Tenon Technology AG, a Swiss company (“TTAG,” and together with the Company and the Purchaser, the “Parties”).

 

RECITALS

 

A.       The
Purchaser is the holder of 574,033 Series A Preferred Shares, i.e. registered preferred shares with a nominal value of CHF 0.40
each in TTAG (the “TTAG Preferred Shares”).

 

B.       Pursuant
to the Shareholders Agreement dated October 3, 2012 among the Parties, as amended pursuant to an Amendment to Shareholders Agreement
dated November 23, 2012 among the Parties (as amended, the “TTAG Shareholders Agreement”), the Purchaser was
granted the right to convert the TTAG Preferred Shares into Series A Preferred Stock of the Company (the “Series A Stock”)
(the “Conversion Right”) upon the IPO (as defined therein) or Sale (as defined therein) of the Company.

 

C.       Section
8.2(d) of the Investment and Subscription Agreement dated November 23, 2012 among the Parties (the “TTAG Investment Agreement”)
provides that the TTAG Shareholders Agreement will grant the Purchaser the Conversion Right at any time.

 

D.       The
Purchaser has entered into a loan agreement dated May 25, 2021 based on which the Purchaser has disbursed to TTAG a loan in the
amount of CHF 100,000 at an interest rate of 8.00%, such loan and interest to be repaid by TTAG to the Purchaser on December
31, 2021 at the latest (the “TTAG Loan”).

 

E.       The
Company desires for the Purchaser to exercise the Conversion Right and the Purchaser accepts to exercise the Conversion Right and
to settle the TTAG Loan pursuant to the terms and conditions of this Agreement.

 

F.       The
Series A Stock have, on the date of this Agreement, the rights, preferences and privileges provided for in the Company’s
Amended and Restated Certificate of Incorporation attached hereto as Exhibit A (the “Restated Certificate”).

 

AGREEMENT

 

Accordingly, the Parties
agree as follows:

 

1.       Conversion.

 

1.1       TTAG
Shareholders Agreement. Each of the Parties acknowledges the discrepancy between the TTAG Shareholders Agreement and the TTAG
Investment Agreement with respect to the Conversion Right and agrees that, notwithstanding that there is neither an IPO nor a Sale
of the Company on the date hereof, the Purchaser is permitted to exercise the Conversion Right on the date hereof. Each of the
Parties further agrees that the Fixed Shareholding in Founder (as defined in the TTAG Shareholders Agreement) on the date hereof
shall be calculated as per this Agreement.

 

    	 	-1-	 

     

    

 

1.2       Ownership
Target. At the Closing (as defined below), Purchaser shall receive in exchange of the TTAG Preferred Shares the number of shares
of Series A Stock equal to 24.00% of the Fully-Diluted Capital of the Company (as defined below) determined as of the Closing,
subject to a subsequent adjustment as provided in Section 2.3 upon the first occurrence of a Trigger Event (as defined below) at
any time following Closing, rounded down to the nearest whole number (the “Ownership Target”). “Fully-Diluted
Capital” of the Company shall mean the sum of (i) the outstanding shares of common stock of the Company; (ii) the shares
of common stock of the Company directly or indirectly issuable upon conversion or exchange of all outstanding securities directly
or indirectly convertible into or exchangeable for common stock of the Company and the exercise of all outstanding options and
warrants; (iii) the shares of common stock of the Company reserved, but neither issued nor the subject of outstanding awards, under
any equity incentive or similar plan of the Company; and (iv) any outstanding convertible promissory notes and any related warrants
and the securities directly or indirectly issuable upon conversion or exchange of such other outstanding convertible promissory
notes and the exercise of any such related warrants. Notwithstanding the foregoing,

 

(a)       shares
issued or issuable following the date hereof (a) upon a financing approved by the Board of Directors of the Company following the
Closing in an aggregate amount of not less than $5,000,000.00, provided that such shares have been or are intended to be issued
(in any case whatsoever) at an issue price of no less than $3.3737 per share or (b) upon an IPO, shall be disregarded for the determination
of the Fully-Diluted Capital (it being understood that all existing shares issued or issuable based on rights granted at the date
of the Closing, including all currently outstanding convertible loans, shall not fall under this provision but be fully considered
for the determination of the Fully-Diluted Capital); and

 

(b)       in
case of a Change of Control Repayment (as defined below), any amount paid to the holder of Relevant Notes in excess of the then
outstanding principal amount and accrued interest of the Relevant Notes (the “Excess Amount”) shall be deemed
as having been converted into the number of shares in the Company equal to the amount resulting by dividing the Excess Amount by
the purchase price per share offered by the third party acquirer(s) triggering the Change of Control (as defined in the subscription
agreement to the Relevant Notes), rounded down to the next integer number (the “Deemed Issued Shares”) and such
Deemed Issued Shares shall be considered when determining the Fully-Diluted Capital (it being understood that in the event of a
Change of Control Repayment of a given Relevant Note, no shares of common stock of the Company will be directly or indirectly issuable
upon conversion or exchange of such Relevant Note, and such securities will not be considered for the determination of the Fully-Diluted
Capital save for the Deemed Issued Shares).

 

Exhibit B
illustrates the Fully-Diluted Capital of the Company immediately prior to an IPO, assuming certain values. For the avoidance of
doubt, Exhibit B shall be illustrative and shall not determine in any way the method for the calculation of the shares to
be allotted to the Purchaser or an anti-dilution adjustment as per Section 2.3 which shall be solely determined by Sections 1 and
2.3.

 

    	 	 	 

     

    

 

1.3       Trigger
Events. Each of the following events shall be deemed a “Trigger Event” upon the occurrence of which the
definitive number of Shares to be allocated to the Purchaser in order to fulfill the Ownership Target shall be determined in accordance
with Sections 1 and 2.3:

 

(a)       the
closing of an IPO;

 

(b)       the
closing of the conversion of the Relevant Notes into stock of the Company;

 

(c)       the
entire repayment of the Relevant Notes in case of a Change of Control (as defined into the subscription agreement to the Relevant
Notes) (a “Change of Control Repayment”);

 

(d)       the
closing of the liquidation of the Company for whatever reason.

 

“Relevant Notes” shall mean
the convertible promissory loan notes issued by the Company in 2021 granting the creditors the right to convert their loans at
the lower of (i) 70% of the IPO price or 70% of the price paid by other investor in a $5,000,000.00 qualified financing or (ii)
the amount obtained by dividing (x) $22,500,000 by (y) the Fully Diluted Capitalization of the Company (as defined in
the subscription agreement to the Relevant Notes). Exhibit B lists the Relevant Notes, it being understood, however, that
also convertible loan notes missing in Exhibit B shall nevertheless be deemed Relevant Notes to the extent such convertible
loan notes have been entered into by the date hereof and grant to the creditors the right to convert their loans at the lower of
(i) 70% of the IPO price or 70% of the price paid by other investor in a $5,000,000.00 qualified financing or (ii) the amount obtained
by dividing (x) $22,500,000 by (y) the Fully Diluted Capitalization of the Company (as defined in the subscription agreement
to the Relevant Notes). For the avoidance of doubt, any refinancing of the Relevant Notes through new loans granted by the holder
of Relevant Notes in replacement of or conjunction with the Relevant Notes as well as any prolongation of the term of Relevant
Notes shall not be deemed a Trigger Event and any such additional or renewed loans shall also be deemed Relevant Notes for the
purpose of this Agreement.

 

2.       Share
Exchange.

 

2.1       Transfer
of TTAG Preferred Shares. At the Closing, and subject to and upon the terms and conditions of this Agreement, the Company shall
purchase, and the Purchaser shall sell, convey, transfer, assign and deliver to the Company, free and clear of all liens, encumbrances
or other defects of title, all of the TTAG Preferred Shares (the “Exchange”).

 

2.2       Issuance
of Series A Stock. In consideration of the sale, conveyance, transfer, assignment and delivery of such TTAG Preferred Shares,
at the Closing and effective upon filing a Certificate of Amendment to the Restated Certificate, the Company shall issue to the
Purchaser 2,550,763 shares of Series A Stock (the “Shares”) and a stock certificate for such number of Shares,
it being understood that the exact number of Shares granted at Closing will be subject to an adjustment per Section 2.3 (Anti-Dilution
Adjustment) considering the fact that the Parties are not able to determine the exact number of Shares to be granted to Purchaser
in order to fulfill the Ownership Target because the shares in the Company to be issued to certain note holders are indeterminate
as of the Closing.

 

    	 	 	 

     

    

 

2.3       Anti-Dilution
Adjustment. The Parties agree that if the Shares do not equal the Ownership Target immediately after a Trigger Event, then
(i) the Company shall issue to Purchaser additional Shares (“Adjustment Shares”) such that the Shares held by
Purchaser shall equal the Ownership Target or (ii) the Purchaser shall contribute a portion of Shares to the Company for no consideration
such that the Shares held by Purchaser then equal the Ownership Target. The Parties further agree that the anti-dilution adjustment
right in this Section 2.3 shall terminate following the occurrence of the first Trigger Event and upon satisfaction of the adjustment
procedure set forth in this Section 2.3.

 

Notwithstanding the foregoing, if the Company
distributes a dividend before a Trigger Event, and should the Shares not equal the Ownership Target immediately prior to the distribution
of the dividend but be less the Ownership Target, the Company shall issue to Purchaser additional Shares such that the Shares held
by Purchaser shall equal the Ownership Target. No such adjustment shall occur in case of a dividend distribution by the Company
if the Shares equal or exceed the Ownership Target immediately prior to the distribution of the dividend. For the avoidance of
doubt, this Section 2.3 and the anti-dilution adjustment right set out herein shall survive an adjustment in case of a dividend
of the Company.

 

3.       TTAG
Loan. 

 

3.1       Purchase
of TTAG Loan. The Purchaser agrees to sell and herewith sells, assigns, transfers and conveys, and the Company agrees to purchase
and herewith purchases and assumes the TTAG Loan in consideration for the outstanding loan amount and all accrued interest at the
date of the Closing (the “TTAG Loan Purchase Price”), subject to Section 3.2).

 

3.2       Condition
for the Assignment of the TTAG Loan. The legal effect of the assignment, transfer and conveyance of the TTAG Loan by the Purchaser
to the Company is conditional (condiction suspensiva) upon the completion of the Closing taking place and shall be only
effective as of the date of the TTAG Loan Purchase Price is credited to the bank account designated by the Purchaser to the Company.

 

4.       Closing;
Deliverables.

 

4.1       Closing.
The closing of the transactions contemplated in Section 2 (the “Closing”) shall be via electronic exchange of
documents and signatures on the date of this Agreement.

 

4.2       Purchaser’s
Deliverables. At the Closing, the Purchaser will:

 

(a)       execute
and deliver Adoption Agreement in substantially the form of Exhibit C;

 

    	 	 	 

     

    

 

(b)       deliver
an assignment document duly executed by the Purchaser evidencing the assignment of the TTAG Preferred Shares to the Company;

 

(c)       deliver
a copy of the board resolution of TTAG approving the transfer of TTAG Preferred Shares and of the TTAG Loan to the Company signed
by the members of the board of directors nominated by the Purchaser;

 

(d)       deliver
TTAG’s share register evidencing the Company as owner of, and as a shareholder with voting rights with respect to, the TTAG
Preferred Shares.

 

4.3       Company’s
Deliverables. At the Closing, the Company will:

 

(a)       deliver
evidence of the acceptance of the Secretary of State of the State of Delaware of the filed Certificate of Amendment to the Restated
Certificate, properly adopted by all necessary corporate action;

 

(b)       deliver
a duly signed notification letter of the ultimate beneficial owner upon receipt of the Purchaser’s Deliverables set forth
in Section 3.2;

 

(c)       deliver
a copy of the board resolution of TTAG approving the transfer of TTAG Preferred Shares and of the TTAG Loan to the Company signed
by the members of the board of directors nominated by the Company;

 

(d)       wire
the TTAG Loan Purchase Price to the bank account designated by the Purchaser (evidenced by receipt of payment slip of Purchaser);

 

(e)       upon
receipt of the Purchaser’s Deliverables set forth in Section 3.2, deliver to the Purchaser a certificate for the Shares;

 

(f)       deliver
copies of the fully executed written consent of the stockholders of the Company (i) waiving the application of Article Fourth,
Section 4(d) of the Charter (as defined below) by the Requisite Holders (as such term is defined in the Charter); (ii) waiving
the preemptive rights (Section 4.1) and notice provisions (Section 5.1) of the Investors' Rights Agreement; (iii) waiving treatment
of the transactions contemplated by this Agreement as a Change in Control under the Relevant Notes, the Voting Agreement (as defined
below), the Co-Sale Agreement (as defined below) and that certain Investors’ Rights Agreement dated as of October 2, 2012
between the Company and the stockholders party thereto (the “Rights Agreement”); (iv) approving the grant of
registration rights pursuant to Section 2.13 the Rights Agreement to the Purchaser by Holders of at least a majority of the Registrable
Securities (as such terms are defined in the Rights Agreement); (v) confirming that the Co-Sale Agreement will terminate upon the
closing of a Qualified Public Offering (as such term is defined in that agreement) rather than on the filing of a registration
statement relating to a Qualified Public Offering and (vi) approving an amendment to the amended and restated certificate of incorporation
of the Company (the "Charter") increasing the number of authorized shares of Series A preferred stock to 2,805,839 shares;

 

    	 	 	 

     

    

 

(g)       deliver
a copy of the side letter executed by the Company granting Purchaser board observation rights;

 

(h)       deliver
a copy of the fully executed waiver of the holders of a majority in interest of the Relevant Notes waiving treatment of the transactions
contemplated by this Agreement as a Change in Control under the Relevant Notes;

 

(i)       confirm
amendment of Exhibit A to the Rights Agreement, the Voting Agreement dated as of October 2, 2012 between the Company and the stockholders
party thereto (the "Voting Agreement") and the Right of First Refusal and Co-Sale Agreement dated as of October 2, 2012
between the Company and the stockholders party thereto (the "Co-Sale Agreement) listing Purchaser as a party to such agreement;

 

(j)       deliver
evidence of the adoption of resolutions of the board of

directors of the Company approving (i) the amendment to the Charter; (ii) the execution delivery and performance of this Agreement
and the issuance of the Shares

and, if necessary, any Adjustment Shares, (iii) reservation of a sufficient number of shares of

common stock of the Company as may be issuable upon conversion of the Series A Preferred Stock;

and (iv) execution and delivery of the Adoption Agreement; and

 

(k)       deliver
a waiver by the Company of any rights arising under Section 14 of the Shareholders Agreement dated October 3, 2012 among Zühlke
Ventures AG, the Company and Tenon Technology AG with respect to the Exchange.

 

5.       Termination
of TTAG Shareholders Agreement and TTAG Investment Agreement. Notwithstanding anything to the contrary set forth in the TTAG
Shareholders Agreement or the TTAG Investment Agreement, the Parties agree that the TTAG Shareholders Agreement and the TTAG Investment
Agreement are each terminated contingent upon and effective as of the Closing, and that any and all rights of the Parties arising
out of either the TTAG Shareholders Agreement or the TTAG Investment Agreement effective after Closing shall hereby be deemed irrevocably
waived upon Closing.

 

6.       Company
Representations and Warranties. The Company represents and warrants to the Purchaser as follows:

 

6.1       Organization
and Good Standing. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of
the State of Delaware. The Company has the requisite corporate power and authority to own and operate its properties and assets,
to carry on its business as presently conducted, to execute and deliver this Agreement, to issue and sell the Shares and to perform
its obligations pursuant to this Agreement and the Restated Certificate.

 

6.2       Capitalization.
As of immediately prior to the sale and issuance of the Shares, the authorized capital stock of the Company consisted of 10,487,904
shares of Common Stock, 1,660,000 shares of which are issued and outstanding, and 3,297,061 shares of Preferred Stock, 2,805,839
of which are designated Series A Preferred Stock, none of which are issued or outstanding, and 491,222 of which are designated
Series B Preferred Stock. The Common Stock, Series A Preferred Stock, and Series B Preferred Stock have the rights, preferences,
privileges and restrictions set forth in the Restated Certificate. The outstanding shares thereof have been duly authorized and
validly issued in compliance with applicable laws, and are fully paid and nonassessable.

 

    	 	 	 

     

    

 

6.3       Authorization.
All corporate action on the part of the Company and its directors, officers and stockholders necessary for the authorization, execution
and delivery of this Agreement by the Company, the authorization, sale, issuance and delivery of the Shares and the performance
of all of the Company’s obligations under this Agreement has been taken or will be taken prior to the Closing. This Agreement,
when executed and delivered by the Company, will constitute a valid and binding obligation of the Company, enforceable in accordance
with its terms, except (i) as limited by laws of general application relating to bankruptcy, insolvency and the relief of
debtors and (ii) as limited by rules of law governing specific performance, injunctive relief or other equitable remedies
and by general principles of equity.

 

6.4       Shares.
The Shares, when issued, delivered and paid for in compliance with the provisions of this Agreement, will be validly issued, fully
paid and nonassessable. The shares of Common Stock issuable upon conversion of the Shares (the “Conversion Shares”)
have been duly and validly reserved and, when issued in compliance with the provisions of this Agreement, the Restated Certificate
and applicable law, will be validly issued, fully paid and nonassessable. The Shares and the Conversion Shares will be free of
any liens or encumbrances, other than any liens or encumbrances created by or imposed upon the Purchaser, provided, however, that
the Shares and the Conversion Shares are subject to restrictions on transfer under U.S. state and/or federal securities laws.

 

6.5       Brokers
or Finders. The Company has not engaged any brokers, finders or agents, and the Company has not and will not incur, directly
or indirectly, as a result of any action taken by the Company, any liability for brokerage or finders’ fees or agents’
commissions or any similar charges in connection with this Agreement.

 

7.       Purchaser
Representations and Warranties. The Purchaser represents and warrants to the Company and TTAG as follows:

 

7.1       Conversion
Right; TTAG. The Purchaser has irrevocably elected to exercise the Conversion Right and, upon the issuance of the Shares and
the termination of the TTAG Shareholders Agreement and the TTAG Investment Agreement in accordance with Section 5, the Purchaser
shall not be a direct or indirect holder of any capital stock of TTAG or of any right to acquire capital stock of TTAG and all
of the Purchaser’s rights in TTAG, including any right to appoint members to the board of directors of TTAG, shall be terminated.

 

7.2       No
Registration. The Purchaser understands that the Shares, and the Conversion Shares, have not been, and will not be, registered
under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from
the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature
of the investment intent and the accuracy of the Purchaser’s representations as expressed herein or otherwise made pursuant
hereto.

 

    	 	 	 

     

    

 

7.3       Investment
Intent. The Purchaser is acquiring the Shares, and the Conversion Shares, for investment for its own account, not as a nominee
or agent, and not with the view to, or for resale in connection with, any distribution thereof, and the Purchaser has no present
intention of selling, granting any participation in or otherwise distributing the same.

 

7.4       Investment
Experience. The Purchaser has substantial experience in evaluating and investing in private placement transactions of securities
in companies similar to the Company and acknowledges that the Purchaser can protect its own interests. The Purchaser has such knowledge
and experience in financial and business matters so that the Purchaser is capable of evaluating the merits and risks of its investment
in the Company.

 

7.5       Speculative
Nature of Investment. The Purchaser understands and acknowledges that the Company has a limited financial and operating history
and that an investment in the Company is highly speculative and involves substantial risks. The Purchaser can bear the economic
risk of the Purchaser’s investment and is able, without impairing the Purchaser’s financial condition, to hold the
Shares and the Conversion Shares for an indefinite period of time and to suffer a complete loss of the Purchaser’s investment.

 

7.6       Access
to Data. The Purchaser has had an opportunity to ask questions of, and receive answers from, the officers of the Company concerning
this Agreement, the exhibits and schedules attached hereto and the transactions contemplated by this Agreement, as well as the
Company’s business, management and financial affairs, which questions were answered to its satisfaction. The Purchaser believes
that it has received all the information that the Purchaser considers necessary or appropriate for deciding whether to purchase
the Shares and the Conversion Shares. The Purchaser is relying solely on its own counsel and not on any statements or representations
of the Company or its agents for legal advice with respect to this investment or the transactions contemplated by this Agreement.

 

7.7       Accredited
Investor. The Purchaser is an “accredited investor” within the meaning of Regulation D, Rule 501(a),
promulgated by the Securities and Exchange Commission under the Securities Act and will submit to the Company such further assurances
of such status as may be reasonably requested by the Company.

 

7.8       Residency.
The Purchaser’s primary resident and/or principal place of business is as set forth on the last page of this Agreement.

 

    	 	 	 

     

    

 

7.9       Rule
144. The Purchaser acknowledges that the Shares and the Conversion Shares must be held indefinitely unless subsequently registered
under the Securities Act or an exemption from such registration is available. The Purchaser is aware of the provisions of Rule 144
promulgated under the Securities Act which permit limited resale of shares purchased in a private placement subject to the satisfaction
of certain conditions, including among other things the existence of a public market for the shares, the availability of certain
current public information about the Company, the resale occurring not less than one year after a party has purchased and paid
for the security to be sold, the sale being effected through a “broker’s transaction” or in transactions directly
with a “market maker” and the number of shares being sold during any three-month period not exceeding specified limitations.
The Purchaser understands that the current public information referred to above is not now available and may not become available.
The Purchaser acknowledges and understands that the Company may not be satisfying the current public information requirement of
Rule 144 at the time the Purchaser wishes to sell the Shares or the Conversion Shares, and that, in such event, the Purchaser
may be precluded from selling such securities under Rule 144, even if the other requirements of Rule 144 have been satisfied.
The Purchaser acknowledges that, in the event all of the requirements of Rule 144 are not met, registration under the Securities
Act or an exemption from registration will be required for any disposition of the Shares or the Conversion Shares. The Purchaser
understands that, although Rule 144 is not exclusive, the Securities and Exchange Commission has expressed its opinion that
persons proposing to sell restricted securities received in a private offering other than in a registered offering or pursuant
to Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is available for such
offers or sales and that such persons and the brokers who participate in the transactions do so at their own risk.

 

7.10       No
Public Market. The Purchaser understands and acknowledges that no public market now exists for any of the securities issued
by the Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities.

 

7.11       Authorization.

 

(a)       The
Purchaser has all requisite power and authority to execute and deliver this Agreement, to purchase the Shares hereunder and to
carry out and perform its obligations under the terms of this Agreement. All action on the part of the Purchaser necessary for
the authorization, execution, delivery and performance of this Agreement, and the performance of all of the Purchaser’s obligations
under this Agreement, has been taken or will be taken prior to the Closing.

 

(b)       This
Agreement, when executed and delivered by the Purchaser, will constitute a valid and legally binding obligation of the Purchaser,
enforceable in accordance with their terms except: (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally and (iii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies or by general principles of
equity.

 

(c)       No
consent, approval, authorization, order, filing, registration or qualification of or with any court, governmental authority or
third person is required to be obtained by the Purchaser in connection with the execution and delivery of this Agreement by the
Purchaser or the performance of the Purchaser’s obligations hereunder.

 

7.12       Brokers
or Finders. The Purchaser has not engaged any brokers, finders or agents, and the Company has not and will not incur, directly
or indirectly, as a result of any action taken by the Purchaser, any liability for brokerage or finders’ fees or agents’
commissions or any similar charges in connection with this Agreement.

 

    	 	 	 

     

    

 

7.13       Tax
Advisors. The Purchaser has reviewed with its own tax advisors the U.S. federal, state, local and foreign tax consequences
of this investment and the transactions contemplated by this Agreement. With respect to such matters, the Purchaser relies solely
on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The Purchaser
understands that it (and not the Company) will be responsible for its own tax liability that may arise as a result of this investment
or the transactions contemplated by this Agreement.

 

7.14       Non-U.S.
Persons.  If the Purchaser is a Non-U.S. Person (as defined below), the Purchaser hereby represents and warrants to the
Company as follows:

 

(a)       This
Agreement is made by the Company in reliance upon the Non-U.S. Person’s representations and warranties made in this Section
6.14.

 

(b)       The
Non-U.S. Person has been advised and acknowledges that: (i) the Shares have not been, and when issued, will not be, registered
under the Act, the securities laws of any state of the United States or the securities laws of any other country; (ii) in issuing
and selling the Shares to the Non-U.S. Person pursuant to this Agreement, the Company is relying upon the “safe harbor”
provided by Regulation S and/or on Section 4(2) under the Act; (iii) it is a condition to the availability of the Regulation S
“safe harbor” that the Shares not be offered or sold in the United States or to a U.S. Person until the expiration
of a period of one (1) year following the Closing (the “Restricted Period”); and (iv) notwithstanding the foregoing,
prior to the expiration of Restricted Period, the Shares may be offered and sold by the holder thereof only if such offer and sale
is made in compliance with the terms of this Agreement and either: (A) if the offer or sale is within the United States or
to or for the account of a U.S. Person, the securities are offered and sold pursuant to an effective registration statement or
pursuant to Rule 144 under the Act or pursuant to an exemption from the registration requirements of the Act; or (B) the
offer and sale is outside the United States and to other than a U.S. Person.

 

(c)       As
used herein, the term “United States” means and includes the United States of America, its territories and possessions,
any State of the United States, and the District of Columbia, and the term “U.S. Person” (as defined in Regulation S)
means:

 

(i)       a
natural person resident in the United States;

 

(ii)       any
partnership or corporation organized or incorporated under the laws of the United States;

 

(iii)       any
estate of which any executor or administrator is a U.S. Person;

 

(iv)       any
trust of which any trustee is a U.S. Person;

 

(v)       any
agency or branch of a foreign entity located in the United States;

 

    	 	 	 

     

    

 

(vi)       any
nondiscretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit
or account of a U.S. Person;

 

(vii)       any
discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated
and (if an individual) resident in the United States; and

 

(viii)       a
corporation or partnership organized under the laws of any foreign jurisdiction and formed by a U.S. Person principally for the
purpose of investing in securities not registered under the Act, unless it is organized or incorporated, and owned, by accredited
investors (as defined in Rule 501(a) under the Act) who are not natural persons, estates or trusts.

 

As used herein, the term
“Non-U.S. Person” means any person who is not a U.S. Person or is deemed not to be a U.S. Person under Rule 902(k)(2)
of the Act.

 

(d)       Such
Non-U.S. Person agrees that with respect to the Shares until the expiration of the Restricted Period:

 

(i)       such
Non-U.S. Person, its agents or its representatives have not and will not solicit offers to buy, offer for sale or sell any of the
Shares, or any beneficial interest therein in the United States or to or for the account of a U.S. Person during the Restricted
Period; and

 

(ii)       notwithstanding
the foregoing, prior to the expiration of the Restricted Period, the Shares may be offered and sold by the holder thereof only
if such offer and sale is made in compliance with the terms of this Agreement and either: (A) if the offer or sale is within
the United States or to or for the account of a U.S. Person, then the securities are offered and sold pursuant to an effective
registration statement or pursuant to Rule 144 under the Act or pursuant to an exemption from the registration requirements
of the Act; or (B) the offer and sale is outside the United States and to other than a U.S. Person; and

 

(iii)       such
Non-U.S. Person shall not engage in hedging transactions with regard to the Shares unless in compliance with the Act.

 

The foregoing restrictions
are binding upon subsequent transferees of the Shares, except for transferees pursuant to an effective registration statement.
Such Non-U.S. Person agrees that after the Restricted Period, the Shares may be offered or sold within the United States or to
or for the account of a U.S. Person only pursuant to applicable securities laws.

 

(e)       Such
Non-U.S. Person has not engaged, nor is it aware that any party has engaged, and such Non-U.S. Person will not engage or cause
any third party to engage, in any directed selling efforts (as such term is defined in Regulation S) in the United States
with respect to the Shares.

 

(f)       Such
Non-U.S. Person: (i) is domiciled and has its principal place of business outside the United States; (ii) certifies it
is not a U.S. Person and is not acquiring the Shares for the account or benefit of any U.S. Person; and (iii) at the time
of the Closing, the Non-U.S. Person or persons acting on Non-U.S. Person’s behalf in connection therewith will be located
outside the United States.

 

    	 	 	 

     

    

 

(g)       At
the time of offering to such Non-U.S. Person and communication of such Non-U.S. Person’s order to purchase the Shares and
at the time of such Non-U.S. Person’s execution of this Agreement, the Non-U.S. Person or persons acting on Non-U.S. Person’s
behalf in connection therewith were located outside the United States.

 

(h)       Such
Non-U.S. Person is not a “distributor” (as defined in Regulation S) or a “dealer” (as defined in the
Act).

 

(i)       Such
Non-U.S. Person acknowledges that the Company shall make a notation in its stock books regarding the restrictions on transfer set
forth in this Section 6 and shall transfer such shares on the books of the Company only to the extent consistent therewith.
In particular, such Non-U.S. Person acknowledges that the Company shall refuse to register any transfer of the Shares not made
in accordance with the provisions of Regulation S, pursuant to registration under the Act or pursuant to an available exemption
from registration.

 

(j)       Such
Non-U.S. Person understands and agrees that each certificate held by such Non-U.S. Person representing the Shares, or any other
securities issued in respect of the Shares upon any stock split, stock dividend, recapitalization, merger, consolidation or similar
event, shall bear the following legend or a substantially similar legend (in addition to any legend required by this Agreement,
by Sections 417 and 418 of the California Corporations Code or under applicable state securities laws):

 

THE SHARES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY
NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S PROMULGATED
UNDER THE SECURITIES ACT, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION.
HEDGING TRANSACTIONS INVOLVING THE SHARES REPRESENTED HEREBY MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.
This certificate must be surrendered to the coMPANY or its transfer agent as a condition
precedent to the sale, pledge, hypothecation or any other transfer of any interest in any of the shares represented by this certificate.

    	 	 	 

     

    

THE SHARES REPRESENTED
BY THIS CERTIFICATE ARE SUBJECT TO (1) RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD IN THE EVENT OF A
PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS’ RIGHTS AGREEMENT, AND (2) VOTING RESTRICTIONS AS SET FORTH IN A VOTING AGREEMENT
AMONG THE COMPANY AND THE ORIGINAL HOLDERS OF THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY.

 

(k)       Such
non-U.S. Person has satisfied as to the full observance of the laws of such non-U.S. Person’s jurisdiction in connection
with any invitation to subscribe for the Shares or any use of the Agreement, including: (i) the legal requirements within
such non-U.S. Person’s jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable
to such purchase, (iii) any governmental or other consents that may need to be obtained and (iv) the income tax and other
tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of such securities. Such
non-U.S. Person’s subscription and payment for, and such non-U.S. Person’s continued beneficial ownership of, the Shares
will not violate any applicable securities or other laws of such non-U.S. Person’s jurisdiction.

 

8.       Miscellaneous.

 

8.1       Waivers
and Amendments. Any term of this Agreement may be amended and the observance of any term hereof or thereof may be waived (either
generally or in a particular instance and either retroactively or prospectively) with the written consent of each of the Parties.

 

8.2       Notices.
All notices and other communications required or permitted hereunder will be in writing and will be mailed by registered or certified
mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand or by messenger addressed:

 

(a)       if
to the Purchaser, to its address or facsimile number listed on the signature page of this Agreement, or to such other address or
facsimile number as the Purchaser will have furnished to the other parties;

 

(b)       if
to the Company, to its address or facsimile number listed on the signature page of this Agreement (Attn: Chief Executive Officer),
or to such other address or facsimile number as the Company will have furnished to the other parties, with a copy to James Huie,
Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304; or

 

(c)       if
to TTAG, to its address or facsimile number listed on the signature page of this Agreement, or to such other address or facsimile
number as TTAG will have furnished to the other parties.

 

With respect to any notice
given by the Company or TTAG hereunder, the Purchaser agrees that such notice may be given by facsimile or by electronic mail.

 

Each such notice or other
communication will for all purposes of this Agreement be treated as effective or having been given when delivered if delivered
personally, or, if sent by mail, at the earlier of its receipt or 72 hours after the same has been deposited in a regularly maintained
receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or, if sent by facsimile, upon confirmation
of facsimile transfer, or, if sent by electronic mail, upon confirmation of delivery.

 

    	 	 	 

     

    

8.3       Governing
Law. This Agreement will be governed in all respects by the internal laws of the State of California as applied to agreements
entered into among California residents to be performed entirely within California, without regard to principles of conflicts of
law.

 

8.4       Expenses.
The Parties will each pay their own expenses in connection with the transactions contemplated by this Agreement; provided,
however, that TTAG shall pay the legal expenses of the Purchaser in connection with the transactions contemplated by this
Agreement.

 

8.5       Successors
and Assigns. This Agreement, and any and all rights, duties and obligations hereunder, will not be assigned, transferred, delegated
or sublicensed by the Purchaser without the prior written consent of the Company and TTAG. Any attempt by the Purchaser without
such permission to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under this Agreement will
be void. Subject to the foregoing and except as otherwise provided herein, the provisions of this Agreement will inure to the benefit
of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

 

8.6       Entire
Agreement. This Agreement, including the exhibits attached hereto, constitutes the full and entire understanding and agreement
among the Parties with regard to the subjects hereof and thereof. No party will be liable or bound to any other party in any manner
with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth
herein or therein.

 

8.7       California
Corporate Securities Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART
OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION IS UNLAWFUL UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION
BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY
CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.

 

8.8       Severability.
If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or
void, portions of such provision, or such provision in its entirety, to the extent necessary, will be severed from this Agreement,
and such court will replace such illegal, void or unenforceable provision of this Agreement with a valid and enforceable provision
that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable
provision. The balance of this Agreement will be enforceable in accordance with its terms.

 

    	 	 	 

     

    

8.9       Counterparts.
This Agreement may be executed in any number of counterparts, each of which will be enforceable against the parties actually executing
such counterparts, and all of which together will constitute one instrument.

 

8.10       Telecopy
Execution and Delivery. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more parties
hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of
or on behalf of such party can be seen. Such execution and delivery will be considered valid, binding and effective for all purposes.
At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any
facsimile, telecopy or other reproduction hereof.

 

8.11       Jurisdiction;
Venue. With respect to any disputes arising out of or related to this Agreement, the Parties consent to the exclusive jurisdiction
of, and venue in, the state courts in Santa Clara County in the State of California (or, in the event of exclusive federal jurisdiction,
the courts of the Northern District of California).

 

8.12       Further
Assurances. Each party hereto agrees to execute and deliver, by the proper exercise of its corporate, limited liability company,
partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may
be necessary to more fully effectuate this Agreement.

 

(The remainder
of this page is intentionally left blank.)

 

    	 	 	 

     

    

 

	 	COMPANY:
	 	 
	 	TENON MEDICAL, INC.
	 	 
	 	By:	 
	 	 
	 	Name:	 
	 	 
	 	Title:	 
	 	 
	 	Address:	 
	 	 
	 	Email:  	 
	 	Facsimile:	 

 

    	 	 	 

     

    

 

	 	PURCHASER:
	 	 
	 	ZÜHLKE VENTURES AG
	 	 
	 	By:	 
	 	 
	 	Name:	 
	 	 
	 	Title:	 
	 	 
	 	Address:	 
	 	 
	 	Email:  	 
	 	Facsimile:	 

 

    	 	 	 

     

    

 

	 	TENON TECHNOLOGY AG
	 	 
	 	By:	 
	 	 
	 	Name:	 
	 	 
	 	Title:	 
	 	 
	 	Address:	 
	 	 
	 	Email:  	 
	 	Facsimile:	 

 

    	 	 	 

     

    

 

EXHIBIT A

 

Amended and Restated Certificate of Incorporation

 

    	 	 	 

     

    

 

EXHIBIT B

 

Excel Spreadsheet

 

    	 	 	 

     

    

 

EXHIBIT C

 

Adoption Agreement

 

This Adoption Agreement
(“Adoption Agreement”) is executed on October ___, 2021, by Zühlke Ventures AG, a Swiss company (the “Holder”)
pursuant to the terms of (i) that certain Investor Rights Agreement dated October 2, 2012, (ii) that certain Voting Agreement dated
October 2, 2012, and (iii) that certain Right of First Refusal and Co-Sale Agreement dated October 2, 2012 (collectively, the “Agreements”),
each by and among the Company and certain of its stockholders, as such Agreements may be amended or amended and restated hereafter.
Capitalized terms used but not defined in this Adoption Agreement shall have the respective meanings ascribed to such terms in
the Agreements. By the execution of this Adoption Agreement, the Holder and the Company agree as follows.

 

1.1       Acknowledgement.
Holder acknowledges that Holder is acquiring certain shares of the capital stock of the Company (the “Stock”)
as an investor, in which case Holder will be an “Investor” for all purposes of the Agreements.

 

1.2       Agreement.
Holder hereby (a) agrees that the Stock, and any other shares of capital stock or securities required by the Agreements to be bound
thereby, shall be bound by and subject to the terms of the Agreements and (b) adopts the Agreements with the same force and effect
as if Holder were originally a party thereto. The Company hereby agrees that the Holder shall be entitled to all rights and privileges
as an Investor under each of the Agreements with the same force and effect as if Holder were originally a party thereto.

 

	ZÜHLKE VENTURES AG	 	ACCEPTED AND AGREED:
	 	 	 
	By:	 	 	TENON MEDICAL, INC.
	Name and Title of Signatory	 	 
	 	 	 
	Address:	 	 	By:	 
	 	 	 	 	 
	 	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]